INTRODUCTION {#s1}
============

As one of the pivotal pathways in maintaining genetic stability, MMR system is mainly in charge of repairing the replication-associated errors, including removing mistaken bases, correcting substitutions and rectifying insertion-deletion mismatches. Its defects may result in microsatellite instability (MSI), a type of genetic instability related to colorectal cancer, gastric cancer, and endometrial cancer, etc. \[[@R1]--[@R3]\] Interest in MLH1 has increased in the last few years because MLH1 was discovered as a key component in MMR for MSI, and its dysfunction is supposed to be implicated in cancer predisposition.

MLH1 not only takes part in the activities of MMR system, but also has other interesting cellular functions, such as participating in cell cycle arrest, triggering DNA damage-induced apoptosis to response to some chemical or physical agents \[[@R4]\], and interacting with tumor-related signaling molecules like BRCA1 \[[@R5]\] and p53 \[[@R6]\]. Moreover, various polymorphisms were found in MLH1 gene, part of them were proved to influence the expression of functional MLH1. We selected three most common loci rs1800734, rs1799977, and rs63750447 in hMLH1 which may alter the function of the hMLH1 gene according to literature. Among these, the A allele of rs1800734 polymorphism could alter the methylation level of nine CpG sites mapped on the MLH1 promoter \[[@R7]\], while rs1799977 and rs63750447 were situated at the exons of hMLH1 \[[@R1], [@R8]\]. Emerging inspiring evidences indicate these functional polymorphisms of hMLH1 may be potential candidates in mediating hereditary susceptibility to cancer, however, applying them in clinical application is still treated critically. Past decades witnessed numerous molecular epidemiological studies carried out worldwide to investigate the actual association between them, yet no coincident conclusion was reached so far.

For example, Nizam et al. \[[@R9]\] concluded that rs1800734 polymorphism had an influence on colorectal cancer (CRC) risk among Malaysians in 2013, while Zhang *et al* \[[@R10]\] found no obvious connection between rs1800734 and CRC risk in 2016. For rs1799977 polymorphism, Milanizadeh et al. \[[@R11]\] detected it could increase CRC risk particularly in female patients, but Peng *et al.* \[[@R1]\] hold a contrary opinion that no association existed between the two. The inconsistent conclusions also existed in the studies exploring the relationship between hMLH1 polymorphisms and other cancer types. Although rs63750447 polymorphism was accepted as a risk factor for east-Asian CRC patients \[[@R1], [@R12]--[@R14]\], no reliable conclusion reported on the possible relationship between rs63750447 and overall cancer or other kinds of tumors. To solved these controversies, a comprehensive and persuasive meta-analysis was excepted to conduct depending on complete published data and proper methodological tools, thus we carried out this meta-analysis to illuminate the objective connection between hMLH1 polymorphisms (rs1800734, rs1799977 and rs63750447) and cancer risk.

RESULTS {#s2}
=======

Characteristics of eligible studies {#s2_1}
-----------------------------------

Finally, we obtained a total of 57 publications including 31,484 cancer cases and 45,494 cancer-free controls (all were from the databases and no study was identified by manual search of the references of the original studies or review articles). The detail selection process was shown in the flow diagram (Figure [1](#F1){ref-type="fig"}). What needed illustration is that we abandon three studies contained in previous meta-analyses after comprehensive reading full text. The first one was the study performed by Chen *et al* \[[@R15]\], contained in the meta-analyses conducted in 2011 \[[@R16]\] and 2015 \[[@R17]\], which was excluded on account of both its cases group and controls group are women with cancers (cases with MLH1 methylation while controls not). Another study finished by van Roon *et al*. \[[@R18]\], also included in previous meta-analyses \[[@R17], [@R19]\], has two controls groups collected from literature \[[@R20], [@R21]\]. We excluded it after discussing with a senior author within us. And the third study we abandoned was due to deficiency of cancer-free control group \[[@R16]\].

![The flow diagram of the meta-analysis, according to the PRISMA 2009\
CNKI = China National Knowledge Infrastructure.](oncotarget-08-93063-g001){#F1}

Among the 57 eligible literatures, 26 were based on Caucasian background from, Poland, Spain, the United States, Denmark, the United Kingdom, Sweden, Portugal, Czech Republic and Canada. 27 were carried out in Asians from China, Kazakhstan, India, Iran, Malaysia, Japan and Korea, and four were based on mixed ethnic groups. All the publications involving rs63750447 polymorphism were carried out among the Chinese population. Three case-cohort designed studies \[[@R22]--[@R24]\] and 54 case-controlled studies were involved in this meta-analysis. All cancer cases were confirmed by pathology or histology, involved cancer types covering colorectal, gastric, ovarian, head and neck, endometrium, lung, bladder, prostate, thyroid, breast, prostate, Non-Hodgkin lymphoma, acute myeloid leukaemia, and acute lymphoblastic leukaemia. The quality assessment of six studies obtained a summarized score less than 6 in terms of the Newcastle-Ottawa Scale (NOS), four of them are studying on rs1800734 \[[@R25]--[@R28]\] while one of them is for rs63750447 \[[@R29]\], and the other one focused on rs1800734 and rs1799977 polymorphisms \[[@R30]\]. Specially, two publications by Zhang et al. \[[@R8]\] and Wang et al. \[[@R29]\] contained four and three independent studies respectively. One study focused on rs1799977 polymorphism by Joshi et al. \[[@R31]\] did not provide complete genotype frequencies. Hence only the dominant model was evaluated. Detail characteristics of eligible publications are displayed in Table [1](#T1){ref-type="table"}.

###### Characteristics of the studies included in the meta-analysis

  First author                 Year   Country      Ethnic      Method              Control      Disease   SNP       NOS
  ---------------------------- ------ ------------ ----------- ------------------- ------------ --------- --------- -----
  Peng \[[@R1]\]               2016   China        Asian       PCR-HRM             Population   CRC       2, 3      7
  Zhang \[[@R10]\]             2016   China        Asian       TaqMan              Hospital     CRC       1         6
  Zhu \[[@R2]\]                2016   China        Asian       TaqMan              Population   GC        1         7
  Djansugurova \[[@R46]\]      2015   Kazakhstan   Asian       PCR-RFLP            Hospital     CRC       1         8
  Niu \[[@R47]\]               2015   China        Asian       PCR-RFLP            Hospital     OC        1, 2      6
  Nogueira \[[@R48]\]          2015   Brazil       Mixed       TaqMan              Hospital     HNSCC     1         6
  Poplawski \[[@R3]\]          2015   Poland       Caucasian   PCR-RFLP            Hospital     EC        1         6
  Slovakova \[[@R49]\]         2015   Slovak       Caucasian   PCR-RFLP            Population   LC        1         8
  Rodriguez \[[@R50]\]         2014   Spain        Caucasian   PCR-RFLP            Hospital     BT        1         6
  Jha \[[@R51]\]               2013   India        Asian       PCR-RFLP            Population   HNSCC     1         7
  Martinez-Uruena \[[@R25]\]   2013   Spain        Caucasian   PCR-RFLP            Hosptal      CRC       1         4
  Milanizadeh \[[@R11]\]       2013   Iran         Asian       PCR-RFLP            Hospital     CRC       2         7
  Nizam \[[@R9]\]              2013   Malaysia     Asian       PCR-RFLP            Hospital     CRC       1         6
  Muniz-Mendoza \[[@R30]\]     2012   Mexico       Mixed       PCR-RFLP            Hospital     CRC       1, 2      4
  Savio \[[@R32]\]             2012   Canada       Caucasian   PCR-RFLP            Population   CRC       1         7
  Xiao \[[@R52]\]              2012   China        Asian       PCR                 Population   GC        1, 2      8
  Zhi \[[@R53]\]               2012   China        Asian       PCR-RFLP            Population   BLC       1         7
  Lacey \[[@R54]\]             2011   Poland       Caucasian   iSelect bead chip   Population   EC        1, 2      8
  Lo \[[@R55]\]                2011   China        Asian       PCR                 Hospital     LC        1         7
  Soni \[[@R56]\]              2011   India        Asian       TaqMan              Hospital     PC        1         6
  Whiffin \[[@R57]\]           2011   UK           Asian       KASPae              Population   CRC       1         8
  Zhi \[[@R58]\]               2011   China        Asian       PCR-RHM             Hospital     GC        1         6
  Langeberg \[[@R59]\]         2010   USA          Caucasian   ABI                 Population   PC        2         7
  Picelli \[[@R22]\]           2010   Sweden       Caucasian   Direct sequencing   Population   CRC       2         7
  Shi \[[@R12]\]               2010   China        Asian       PCR                 Hospital     TC        1, 2, 3   6
  Campbell \[[@R41]\]          2009   USA          Caucasian   PCR-RFLP            Population   CRC       1, 2      8
  Conde \[[@R37]\]             2009   Portugal     Caucasian   QIAamp              Hospital     BC        2         6
  Joshi \[[@R31]\]             2009   USA          Caucasian   TaqMan              Population   CRC       2         7
  Nejda \[[@R38]\]             2009   Spain        Caucasian   PCR-RFLP            Hospital     CRC       2         7
  Ohsawa \[[@R13]\]            2009   Japan        Asian       PCR-RFLP            Unknown      CRC       3         6
  Shih \[[@R33]\]              2009   China        Asian       PCR-RFLP            Population   LC        1         7
  Tanaka \[[@R60]\]            2009   Japan        Asian       Direct sequencing   Population   PC        2         7
  An \[[@R61]\]                2008   China        Asian       PCR-RFLP            Population   LC        1, 2      8
  Christensen \[[@R23]\]       2008   Denmark      Caucasian   SBE-tags            Population   CRC       2         8
  Harlay \[[@R26]\]            2008   Canada       Mixed       MassARRAY           Hospital     OC        1         5
  Koessler \[[@R62]\]          2008   UK           Caucasian   TaqMan              Population   CRC       1         7
  Samowitz \[[@R20]\]          2008   USA          Caucasian   Direct sequencing   Population   CRC       1         7
  Scott \[[@R34]\]             2008   UK           Caucasian   TaqMan              Population   NHL       1         6
  Tulupova \[[@R63]\]          2008   Czech        Caucasian   TaqMan              Hospital     CRC       1         7
  Worrillow \[[@R64]\]         2008   UK           Caucasian   PCR-RFLP            Population   AML       1         6
  Berndt \[[@R24]\]            2007   USA          Caucasian   TaqMan              Population   CRC       2         8
  Raptis \[[@R21]\]            2007   Canada       Caucasian   TaqMan              Population   CRC       1, 2      7
  Beiner \[[@R35]\]            2006   Canada       Mixed       MassARRAY           Hospital     EC        1         6
  Landi \[[@R65]\]             2006   Mixed        Caucasian   PCR                 Hospital     LC        2         7
  Mei \[[@R14]\]               2006   China        Asian       PCR                 Hospital     CRC       2, 3      6
  Song \[[@R39]\]              2006   Mixed        Caucasian   TaqMan              Population   OC        1, 2      6
  Chen \[[@R66]\]              2005   China        Asian       PCR-RFLP            Hospital     HCC       1         7
  Lee \[[@R67]\]               2005   Korea        Caucasian   MassARRAY           Hospital     BC        1         6
  Kim \[[@R68]\]               2004   Korea        Asian       TaqMan              Population   CRC       2         6
  Listgarten \[[@R40]\]        2004   Canada       Caucasian   QIAmp               Hospital     BC        2         6
  Park \[[@R36]\]              2004   Korea        Caucasian   PCR                 Population   LC        1         8
  Zhang \[[@R8]\]              2004   China        Asian       DHPLC               Population   Mixed     3         7
  Deng \[[@R69]\]              2003   China        Asian       DHPLC               Hospital     GC        1         7
  Mathonnet \[[@R70]\]         2003   Canada       Caucasian   PCR-ASO             Population   ALL       2         6
  Shin \[[@R27]\]              2002   Korea        Asian       PCR-SSCP            Hospital     CRC       1         4
  Wang \[[@R29]\]              2000   China        Asian       PCR-SSCP            Hospital     Mixed     3         5
  Ito \[[@R28]\]               1999   Japan        Asian       PCR-SSCP            Hospital     CRC       1         4

Quantitative synthesis {#s2_2}
----------------------

The distributions of genotypes frequencies of hMLH1 polymorphisms (rs1800734; rs1799977; rs63750447) for every single study are exhibited in Table [2](#T2){ref-type="table"}. The minor allele frequencies (MAF) among cancer cases varied widely according to the included studies, ranging from 0.205 to 0.656 for rs1800734 polymorphism, 0.016 to 0.744 for rs1799977 polymorphism, and 0.032 to 0.069 for rs63750447 polymorphism. The average MAF of case-group for the three polymorphisms is 0.396, 0.233, 0.053, respectively. The meta-analysis results of these three polymorphisms were shown in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}.

###### Genotype distribution and allele frequency of hMLH1 polymorphisms

  First author                     Genotype (N)   Allele frequency (N)   MAF    HWE                                                                    
  -------------------------------- -------------- ---------------------- ------ ----- ------ ------ ------ ----- ------- ------ ------- ------ ------- -------
  **-93G\>A (rs1800734)**                                                                                                                              
  Zhang 2016 \[[@R10]\]            312            66                     139    107   300    52     154    94    271     353    258     342    0.566   0.414
  Zhu 2016 \[[@R2]\]               406            49                     213    144   444    79     235    130   311     501    393     495    0.617   0.125
  Niu 2015 \[[@R47]\]              421            51                     188    182   689    150    356    183   290     552    656     722    0.656   0.348
  Djansugurova 2015 \[[@R46]\]     249            126                    94     29    244    101    115    28    346     152    317     171    0.305   0.581
  Nogueira 2015 \[[@R48]\]         450            248                    171    31    450    269    159    22    667     233    697     203    0.259   0.809
  Poplawski 2015 \[[@R3]\]         100            18                     81     1     100    9      50     41    117     83     68      132    0.415   0.254
  Slovakova 2015 \[[@R49]\]        422            250                    144    28    511    260    228    23    644     200    748     274    0.237   0.002
  Rodriguez 2014 \[[@R50]\]        115            61                     44     10    200    115    79     6     166     64     309     91     0.278   0.080
  Jha 2013 \[[@R51]\]              245            52                     90     100   205    98     79     28    194     290    275     135    0.599   0.067
  Martinez-Uruena2013 \[[@R25]\]   383            233                    131    19    236    129    102    5     597     169    360     112    0.221   0.003
  Nizam 2013 \[[@R9]\]             104            22                     50     32    104    33     33     38    94      114    99      109    0.548   0.000
  Muniz-Mendoza2012 \[[@R30]\]     100            47                     44     9     115    39     55     21    138     62     133     97     0.310   0.835
  Savio 2012 \[[@R32]\]            252            150                    96     6     845    528    264    53    396     108    1320    370    0.214   0.012
  Xiao 2012 \[[@R52]\]             554            104                    262    188   588    124    271    193   470     638    519     657    0.576   0.113
  Zhi 2012 \[[@R53]\]              311            43                     163    105   302    41     161    100   249     373    243     361    0.600   0.059
  Larcy 2011 \[[@R54]\]            414            251                    141    22    404    241    146    17    643     185    628     180    0.223   0.381
  Lo 2011 \[[@R55]\]               719            235                    344    140   728    256    366    106   814     624    878     578    0.434   0.177
  Soni 2011 \[[@R56]\]             105            44                     40     21    106    27     61     18    128     82     115     97     0.390   0.101
  Whiffin 2011 \[[@R57]\]          10409          6408                   3504   497   6965   4395   2261   309   16320   4498   11051   2879   0.216   0.401
  Zhi 2011 \[[@R58]\]              236            36                     111    89    240    42     114    84    183     289    198     282    0.612   0.757
  Shi 2010 \[[@R12]\]              204            40                     102    62    204    34     99     71    182     226    167     241    0.554   0.959
  Campbell 2009 \[[@R33]\]         1600           952                    553    95    1963   1170   688    105   2457    743    3028    898    0.232   0.769
  Shih 2009 \[[@R33]\]             165            41                     64     60    193    36     113    44    146     184    185     201    0.558   0.016
  An 2008 \[[@R61]\]               500            163                    243    94    517    169    258    90    569     431    596     438    0.431   0.618
  Harley 2008 \[[@R26]\]           842            483                    297    62    776    532    206    38    1263    421    1270    282    0.250   0.003
  Koessler 2008 \[[@R62]\]         2288           1407                   778    103   2276   1392   777    107   3592    984    3561    991    0.215   0.914
  Samowitz 2008 \[[@R20]\]         1006           610                    344    52    1963   1170   688    105   1564    448    3028    898    0.223   0.769
  Scott 2008 \[[@R34]\]            601            375                    205    21    942    610    310    22    955     247    1530    354    0.205   0.016
  Tulupova 2008 \[[@R63]\]         619            359                    216    44    611    365    209    37    934     304    939     283    0.246   0.336
  Worrillow 2008 \[[@R64]\]        390            246                    128    16    918    585    292    41    620     160    1462    374    0.205   0.554
  Raptis 2007 \[[@R21]\]           929            554                    331    44    1098   687    352    59    1439    419    1726    470    0.226   0.118
  Beiner 2006 \[[@R35]\]           654            377                    220    57    764    524    202    38    974     334    1250    278    0.255   0.002
  Song 2006 \[[@R39]\]             1306           825                    414    67    1951   1224   638    89    2064    548    3086    816    0.210   0.615
  Chen 2005 \[[@R66]\]             545            86                     261    198   374    85     178    111   433     657    348     400    0.603   0.400
  Lee 2005 \[[@R67]\]              783            201                    348    234   594    117    292    185   750     816    526     662    0.521   0.927
  Park 2004 \[[@R36]\]             372            66                     176    130   371    71     206    94    308     436    348     394    0.586   0.027
  Deng 2003 \[[@R69]\]             54             8                      27     19    56     9      29     18    43      65     47      65     0.602   0.636
  Shin 2002 \[[@R27]\]             139            33                     61     45    157    42     74     41    127     151    158     156    0.543   0.473
  Ito 1999 \[[@R28]\]              27             8                      10     9     84     22     46     16    26      28     90      78     0.519   0.355
  **655A\>G(rs1799977)**                                                                                                                               
  Peng2016 \[[@R1]\]               156            151                    5      0     311    307    4      0     307     5      618     4      0.016   0.909
  Niu 2015 \[[@R47]\]              418            383                    33     2     689    613    75     1     799     37     1301    77     0.044   0.406
  Milanizadeh 2013 \[[@R11]\]      219            25                     62     132   248    54     119    75    112     326    227     269    0.744   0.599
  Muniz-Mendoza 2012 \[[@R30]\]    102            71                     26     5     100    81     19     0     168     36     181     19     0.176   0.294
  Xiao 2012 \[[@R52]\]             554            522                    31     1     592    568    23     1     1075    33     1159    25     0.030   0.143
  Larcy 2011 \[[@R54]\]            417            210                    160    47    406    196    165    45    580     254    557     255    0.305   0.253
  Langeberg 2010 \[[@R59]\]        1251           578                    555    118   1236   607    514    115   1711    791    1728    744    0.316   0.681
  Picelli 2010 \[[@R22]\]          1781           819                    781    181   1701   832    708    161   2419    1143   2372    1030   0.321   0.560
  Shi 2010 \[[@R12]\]              204            185                    17     2     204    192    11     1     387     21     395     13     0.051   0.072
  Campbell 2009 \[[@R41]\]         1601           764                    678    159   1944   937    848    159   2206    996    2722    1166   0.311   0.087
  Conden 2009 \[[@R37]\]           287            129                    129    29    546    255    251    40    387     187    761     331    0.326   0.039
  Joshi 2009 \[[@R31]\]            301            161                    /      /     354    194    /      /     /       /      /       /      /       /
  Nejda 2009 \[[@R38]\]            140            41                     72     27    125    64     44     17    154     126    172     78     0.450   0.044
  Tanaka 2009 \[[@R60]\]           177            159                    16     2     131    120    11     0     334     20     251     11     0.056   0.616
  An 2008 \[[@R61]\]               500            479                    20     1     504    493    11     0     978     22     997     11     0.022   0.804
  Christensen 2008 \[[@R23]\]      380            172                    170    38    770    364    327    79    514     246    1055    485    0.324   0.661
  Berndt 2007 \[[@R24]\]           211            100                    94     17    2090   968    896    226   294     128    2832    1348   0.303   0.387
  Raptis 2007 \[[@R21]\]           929            451                    391    87    1098   514    485    99    1293    565    1513    683    0.304   0.310
  Landi 2006 \[[@R65]\]            291            145                    123    23    309    129    151    29    413     169    409     209    0.290   0.107
  Mei 2006 \[[@R14]\]              160            144                    14     2     150    141    9      0     302     18     291     9      0.056   0.705
  Song 2006 \[[@R39]\]             1022           507                    418    97    1224   624    477    123   1432    612    1725    723    0.299   0.026
  Kim 2004 \[[@R68]\]              107            100                    7      0     330    311    18     1     207     7      640     20     0.033   0.192
  Listgarten 2004 \[[@R40]\]       170            89                     64     17    156    76     75     5     242     98     227     85     0.288   0.008
  Mathonnet 2003 \[[@R70]\]        287            149                    112    26    320    154    132    34    410     164    440     200    0.286   0.474
  **1151T\>A(rs63750447)**                                                                                                                             
  Peng2016 \[[@R1]\]               156            142                    13     1     311    310    1      0     297     15     621     1      0.048   0.977
  Shi 2010 \[[@R12]\]              204            178                    24     2     204    191    12     1     380     28     394     14     0.069   0.108
  Ohsawa 2009 \[[@R13]\]           670            630                    39     1     332    327    5      0     1299    41     659     5      0.031   0.890
  Mei 2006 \[[@R14]\]              160            142                    18     0     150    141    9      0     302     18     291     9      0.056   0.705
  Zhang 2004 (EC) \[[@R8]\]        233            206                    27     0     268    251    17     0     439     27     519     17     0.058   0.592
  Zhang 2005 (CRC) \[[@R8]\]       90             82                     8      0     268    251    17     0     172     8      519     17     0.044   0.592
  Zhang 2004 (BC) \[[@R8]\]        111            104                    7      0     268    251    17     0     215     7      519     17     0.032   0.592
  Zhang 2004 (GC) \[[@R8]\]        273            240                    33     0     268    251    17     0     513     33     519     17     0.060   0.592
  Wang 2000 (CRC) \[[@R29]\]       101            88                     13     0     100    94     6      0     189     13     194     6      0.064   0.757
  Wang 2000 (EC) \[[@R29]\]        76             69                     7      0     100    94     6      0     145     7      194     6      0.046   0.757
  Wang 2000 (GC) \[[@R29]\]        79             68                     11     0     100    94     6      0     147     11     194     6      0.070   0.757

A: the major allele, B: the minor allele, MAF: minor allele frequencies; HWE: Hardy--Weinberg equilibrium.

Rs1800734 polymorphism {#s2_3}
----------------------

Overall, there are 39 studies including 29,331 cases and 29,588 controls for rs1800734 polymorphism. Statistically significance was found between rs1800734 polymorphism and overall cancer risk under five genetic models (recessive comparison: OR = 1.22, 95%CI = 1.09-1.37, *P* = 0.001; homozygote comparison: OR = 1.23, 95%CI = 1.06-1.42, *P* = 0.006; allele comparison: OR = 1.08, 95%CI = 1.01-1.16, *P* = 0.023). After excluding nine studies that were not in accordance with HWE \[[@R3], [@R9], [@R25], [@R26], [@R32]--[@R36]\], we observed increased risks of all kinds of cancers under two genetic models (recessive comparison: OR = 1.18, 95%CI = 1.04-1.34, *P* = 0.012; homozygote comparison: OR = 1.18, 95%CI = 1.00-1.39, P = 0.048, Figure [2A](#F2){ref-type="fig"}).

![Forest plot of OR with 95%CI for the hMLH1 polymorphisms with cancer risk under dominate model according to HWE (**(A)** rs1800734; **(B)** rs1799977; **(C)** rs63750447). CI: confidence interval, OR: odds ratio, HWE: Hardy-Weinberg equilibrium.](oncotarget-08-93063-g002){#F2}

In the stratification analysis based on ethnicity (Figure [3A](#F3){ref-type="fig"}), we found no association between cancer risk and Caucasian population, while the mutation allele A contributed to an increasing cancer risk in Asian population under three comparison models (recessive comparison: OR = 1.30, 95%CI = 1.11-1.53, *P* = 0.001; homozygote comparison: OR = 1.37, 95%CI = 1.09-1.72, *P* = 0.006; allele comparison: OR = 1.16, 95%CI = 1.03-1.31, *P* = 0.014). In the cancer-specific analysis, rs1800734 polymorphism showed a potential tendency to enhance gastric and lung cancer susceptibility in different genetic comparisons (gastric cancer: dominate comparison: OR = 1.27, 95%CI = 1.03-1.56, *P* = 0.024; homozygote comparison: OR = 1.33, 95%CI = 1.06-1.68, *P =* 0.019, allele comparison: OR = 1.14, 95%CI = 1.02-1.28, *P* = 0.017; lung cancer: recessive comparison: OR = 1.27, 95%CI = 1.03-1.57, *P* = 0.024). Besides, the subgroup analysis depended on the source of controls suggested us that rs1800734 polymorphism had an influence on cancer risk under four genetic models among population-based controls (dominate comparison: OR = 1.05, 95%CI = 1.01-1.10, *P* = 0.016, recessive comparison: OR = 1.12, 95%CI = 1.04-1.22, *P* = 0.004; homozygote comparison: OR = 1.22, 95%CI = 1.00-1.49, *P =* 0.050; heterozygous comparison: OR = 1.05, 95%CI = 1.01-1.10, *P* = 0.031; allele comparison: OR = 1.10, 95% = 1.00-1.20, *P* = 0.041) and recessive comparison among hospital-based controls (OR = 1.27, 95%CI = 1.03-1.57, *P* = 0.024). And, when the subgroup analysis was conducted based on a quality score, rs1800734 polymorphism displayed an increased cancer risk among high-quality studies, but no association was found among low-quality studies ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}).

![Stratified analysis by ethnicity for the association between hMLH1 polymorphisms and cancer risk under homozygote model according to HWE (**(A)** rs1800734; **(B)** rs1799977). CI: confidence interval, OR: odds ratio, HWE: Hardy-Weinberg equilibrium.](oncotarget-08-93063-g003){#F3}

Rs1799977 polymorphism {#s2_4}
----------------------

We finally derived 11,665 cases and 15,538 controls from 24 eligible studies for rs1799977 polymorphism. All the studies obtained high-quality scores according to the Newcastle-Ottawa Scale (NOS). In general, we found the variant G allele of rs1799977 could improve overall cancer risks under three genetic models (dominant comparison: OR = 1.28, 95%CI = 1.16-1.41, *P* \< 0.0001; homozygote comparison: OR = 1.15, 95%CI = 1.04-1.27, *P* = 0.006; allele comparison: OR = 1.12, 95%CI = 1.02-1.23, *P* = 0.017). After excluding four studies \[[@R37]--[@R40]\] that were not in accordance with HWE (Figure [2B](#F2){ref-type="fig"}), the pooled ORs and 95%CI revealed a possible increased risk of cancer (dominant comparison: OR = 1.25, 95%CI = 1.18-1.33, *P* \< 0.0001; homozygote comparison: OR = 1.13, 95%CI = 1.01-1.26, *P* = 0.027).

When the subgroup carried out by ethnicity (Figure [3B](#F3){ref-type="fig"}), a significant association was observed between rs1799977 and cancer risk among Asians in four genetic models (dominant comparison: OR = 1.52, 95%CI = 1.04-2.24, *P* = 0.033; recessive comparison: OR = 3.34, 95%CI = 2.33-4.78, *P* \< 0.0001; homozygote comparison: OR = 3.44, 95%CI = 2.12-5.59, *P* \< 0.0001; allele comparison: OR = 1.64, 95%CI = 1.38-1.95, *P* \< 0.0001) and Caucasians in only dominant model (OR = 1.24, 95%CI = 1.16-1.32, *P* \< 0.0001). In the cancer-specific analysis (Figure [4A](#F4){ref-type="fig"}), rs1799977 polymorphism showed a correlation between colorectal cancer under two genetic models (dominant comparison: OR = 1.32, 95%CI = 1.16-1.51, *P* \< 0.0001; allele comparison: OR = 1.21, 95%CI = 1.03-1.42, *P* = 0.023) and prostate cancer under dominant model (OR = 1.36, 95%CI = 1.16-1.59, *P* \< 0.0001).

![Stratified analysis by cancer type for the association between hMLH1 polymorphisms and cancer risk under dominant model according to HWE (**(A)** rs1799977; **(B)** rs63750447). CI: confidence interval, OR: odds ratio. CRC: colorectal cancer; GC: gastric cancer; BC: breast cancer; PC: prostate cancer; EC: endometrial cancer; OC: ovarian carcinoma; GC: gastric cancer; LC: lung cancer; other: other cancer; HWE: Hardy-Weinberg equilibrium.](oncotarget-08-93063-g004){#F4}

Besides, the results of subgroup analyses by source of control and study design exhibited in the [Supplementary Table 1](#SD2){ref-type="supplementary-material"}.

Rs63750447 polymorphism {#s2_5}
-----------------------

A total of 2153 cancer cases and 1365 cancer-free controls from 11 studies were involved in our meta-analysis for rs63750447 polymorphism. Since the homozygous mutant AA of rs63750447 polymorphism was in very rare frequencies, we chose allele model, heterozygous model and dominant model to evaluate the association strength. The pooled analysis observed a significant association between cancer risk and rs63750447 polymorphism (dominant comparison: OR = 2.23, 95%CI = 1.75-2.86, *P* \< 0.0001; heterozygote comparison: OR = 2.21, 95%CI = 1.73-2.84, *P* \< 0.0001; allele comparison: OR = 2.19, 95%CI = 1.72-2.78, *P* \< 0.0001), as shown in Figure [2C](#F2){ref-type="fig"}.

The subgroup analysis by cancer type (Figure [4B](#F4){ref-type="fig"}) indicated that rs63750447 polymorphism had influences on colorectal cancer (dominant comparison: OR = 2.87, 95%CI = 1.42-5.82, *P* = 0.003; heterozygote comparison: OR = 2.81, 95%CI = 1.42-5.57, *P* = 0.003; allele comparison: OR = 2.84, 95%CI = 1.38-5.81, *P* = 0.004), gastric cancer (dominant comparison: OR = 2.15, 95%CI = 1.27-3.64, *P* = 0.005; heterozygote comparison: OR = 2.2115, 95%CI = 1.27-3.64, *P* = 0.005; allele comparison: OR = 2.19, 95%CI = 1.24-3.47, *P* = 0.006), and endometrium cancer (dominant comparison: OR = 2.23, 95%CI = 1.06-3.21, *P*= 0.029; heterozygote comparison: OR = 1.85, 95%CI = 1.06-3.21, *P* = 0.029; allele comparison: OR = 1.80, 95%CI = 1.05-3.09, *P* = 0.033). When we conducted the subgroup analysis by quality score, there was a significantly increased cancer risk for rs63750447 polymorphism in both high-quality studies and low-quality studies (shown in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}).

Test of heterogeneity and sensitivity analysis {#s2_6}
----------------------------------------------

As shown in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}, significant heterogeneities existed after pooled the data of rs1800734 and rs1799977 polymorphisms under different comparison models (*P* ≤ 0.10 or I^2^ ≥ 50%), thus further subgroup analyses base on ethnicity, cancer type, source of control, and quality scores were performed. No obvious heterogeneity was found for rs63750447 polymorphism (*P* \> 0.10 or I^2^ \< 50%). Subsequent sensitivity analysis proved the stability of our study, since no significant alteration was detected after removing each individual study and rechecking the pooled ORs and 95%CIs for the rs1800734 and rs1799977 polymorphisms (Figure [5A, 5B](#F5){ref-type="fig"}). The third study performed by Zhang et al seemingly altered the pooled ORs significantly (Figure [5](#F5){ref-type="fig"}), and the detailed data from Stata 14.0 also showed us it was nearly approached to the upper limit. We guess it was due to the sample size of rs63750447 polymorphism was insufficient, only 11 studies from 6 articles were included. It indicated us the overall results of rs63750447 should be treated more carefully.

![Sensitivity analysis of the associations between hMLH1 polymorphisms and cancer risk according to HWE (**(A)** rs1800734; **(B)** rs1799977; **(C)** rs63750447). HWE: Hardy-Weinberg equilibrium.](oncotarget-08-93063-g005){#F5}

Publication bias {#s2_7}
----------------

The possible publication bias in the eligible literature was evaluated by Egger\'s test and funnel plots. As shown in Figure [6](#F6){ref-type="fig"}, the Begg\'s funnel plots appear to be symmetrical. This symmetry was then confirmed by the statistical results of Egger\'s test (P \> 0.05, shown in Table [3](#T3){ref-type="table"}). These provided evidence for the absence of publication bias.

![Funnel plots of publication bias (**(A)** rs1800734; **(B)** rs1799977; **(C)** rs63750447).](oncotarget-08-93063-g006){#F6}

###### Egger\'s test for publication bias test of hMLH1 polymorphisms

  Egger\'s test   SE      Coef       Std. Err   t       P\>\|t\|   95%CI
  --------------- ------- ---------- ---------- ------- ---------- -------------------------
  rs1800734       slope   0.06249    0.064308   0.97    0.337      \[-0.067807, 0.192794\]
                  bias    0.15166    0.749679   0.20    0.841      \[-1.367335, 1.670654\]
  rs1799977       slope   0.17888    0.082661   2.16    0.042      \[0.007456, 0.350311\]
                  bias    0.48454    0.597343   0.81    0.426      \[-0.754272, 1.723357\]
  rs63750447      slope   -0.12387   0.497384   -0.25   0.809      \[-1.249034, 1.001287\]
                  bias    2.03105    1.146982   1.77    0.110      \[-0.563603, 4.625704\]

SE: standard error; 95%CI: 95% confidence interval.

DISCUSSION {#s3}
==========

To elucidate the veritable relationship between three hMLH1 polymorphisms (rs1800734; rs1799977; rs63750447) and cancer risk, we performed this meta-analysis based on overall published data up to May 2017. We found all of these polymorphisms can enhance overall cancer risks, especially Asians, under different genetic comparisons ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). Further subgroup analyses were carried out according to cancer type, source of control, quality score, and study design, and results worth discussing were obtained.

Interestingly, we found a moderate association existing between rs1800734 and the risk of gastric cancer in three genetic models (OR = 1.14, *P* = 0.017; OR = 1.33, *P* = 0.019; OR = 1.27, *P* = 0.024) and lung cancer in recessive model (OR = 1.27, *P* = 0.024), while no connection was display with colorectal cancer. As far as we know now, microsatellite instability (MSI) often occurs when mismatch errors failed to be corrected or hMLH1 gene was epigenetic silencing. Campbell et al. \[[@R41]\] found rs1800734 polymorphism enhanced MSI-positive colorectal cancer, the association was proved by Mrkonjic et al. \[[@R42]\] due to the effects of rs1800734 on the MLH1 promoter methylation, immunohistochemistry (IHC) deficiency, or both. This indicated us when performing further studies focused on the relationship between rs1800734 and cancer risk, the MSI-statue of cancer patients should be evaluated fundamentally.

Rs1799977 was a nonsynonymous coding polymorphism in hMLH1, which leaded to an amino acid change from isoleucine to valine. The mutational G allele of rs1799977 polymorphism was proved to connect with susceptibility of colorectal cancer and prostate cancer. For rs63750447, the cancer-specific analysis showed an increased risk of colorectal cancer, endometrial cancer and gastric cancer. Recently, rs63750447 was observed over-expressed in patients with EGFR-TKI (epidermal growth factor receptor-tyrosine kinase inhibitor) resistance, which has a possible shorter progression-free survival \[[@R43]\]. Thus, it was speculated that MLH1 might be involved in EGFR signaling or other pathways (such as proliferation and survival) \[[@R1]\].

Compare with previous meta-analyses study on the association between hMLH1 and cancer risk, our study included a larger sample size and performed more detailed stratification analysis. Besides, our study has stricter inclusion criteria and exclude criteria, thus avoided omissive and false drop (refer to the section of Characteristics of eligible studies, paragraph one). Thus, we think our results are more reliable and convinced. Moreover, we found rs1800734 was related to gastric cancer, while rs1799977 may have an influence on colorectal and prostate cancer. It may give us some hints for the further study.

There are still some limitations existing in this meta-analysis. Firstly, insufficiency of original data limited us to proceed more accurate analyses on the potential interaction between these polymorphisms and other risk factors such as age, sex, hereditary background, lifestyle, and MSI status, etc. Secondly, the studies involved in the rs63750447 analysis was insufficient, whose statistical significance was needed to verify by further well-designed study with larger sample sizes. Thirdly, we couldn\'t exclude the publication bias absolutely according to the negative results of Egger\'s test and funnel plots. Fourthly, the sample size was still small for any given cancer type, although we have pooled all published literatures. Hence, all the three hMLH1 polymorphisms were associated with cancer risk, but further profoundly investigation was requisite to clarify the strength of these associations.

MATERIALS AND METHODS {#s4}
=====================

PRISMA statement was used to guide the process of this meta-analysis \[[@R44]\].

Search strategy {#s4_1}
---------------

A comprehensive literature search was conducted using the following search terms: ("cancer", "carcinoma", "tumor", "tumour", or "neoplasm") and ("polymorphism", "variation", "variant", or "mutation") and ("hMLH1"). The PubMed, Web of knowledge, VIP, WanFang and Chinese National Knowledge Infrastructure (CNKI) databases were searched up to May, 2017. Additional studies were identified by manual search of the references of the original studies or review articles. This study was approved by the ethics committee of Xi'an Jiaotong University.

To be eligible for this meta-analysis, the included study was required to (1) be case-control or case-cohort studies; (2) focused on the relationship between hMLH1 polymorphisms and risk of any cancer; (3) have at least three articles for each studied hMLH1 polymorphism, and available information concerning the genotype frequency of each included SNP of hMLH1 (i.e., rs1800734; rs1799977; rs63750447); (4) be published in English or Chinese. The exclusion criteria were as follows: (1) studies were not focused on cancer risk or targeted hMLH1 SNPs (rs1800734; 2: rs1799977; 3: rs63750447); (2) studies failed to supply any data on genotype distribution, (3) studies were updated by a following study where a larger number of subjects were included, (4) studies were designed as a case-case or case-only study. If 2 or more studies contained overlapping data, we selected the paper included more samples. Studies containing two or more case-control groups were considered as two or more independent studies.

Data extraction and quality assessment {#s4_2}
--------------------------------------

For each included study, two investigators independently extracted the raw data and demographic information, including publication year, first author, ethnicity and country or origin, the number of cases and controls, source of controls, genotyping methods, genetic distribution, and P value of Hardy-Weinberg equilibrium (HWE) among the controls. Studies not follow HWE were excluded in subgroup analysis. We applied the Newcastle-Ottawa Scale (NOS) to evaluate the methodological quality of the eligible studies according to Zeng et al \[[@R45]\]. Accumulated score ranges from 0 to 9 points, and a score of 0-5 and 6-9 is considered to suggest a low and high quality respectively, with higher quality representing lower risks of bias. A discussion or consultation with a senior author was conducted to settle controversy until a consensus was reached.

Statistical analysis {#s4_3}
--------------------

To evaluate the strength of association between hMLH1 polymorphisms (rs1800734; rs1799977; rs63750447) and cancer risk, we calculated the odds ratios (ORs) and 95% confidence intervals (CIs) based on the genotype and allele frequencies in cases and controls of each eligible study. We used the Z test to access the significance of all pooled ORs and it was considered statistically significant if the P value \< 0.05. The Chisquare-based Q statistic test and I^2^ statistic were applied to examine the statistical heterogeneity among studies. When no obvious heterogeneity existed across the studies (P\>0.10 or I^2^ \<50%), we pooled the ORs using fixed-effect model (Mantel-- Haenszel); otherwise, the random effects model (DerSimonian and Laird) was chosen. The potential publication bias was evaluated by funnel plot and Egger\'s test. To access the stability of the results in this meta-analysis, we performed sensitivity analysis by sequentially excluding each study and rechecked whether the pooled ORs were altered significantly.

The following genetic models were evaluated: allele comparison (B vs. A), homozygote comparison (BB vs. AA), heterozygote comparison (AB vs. AA), recessive model (BB vs. AA+ AB), and dominant model (BB+ AB vs. AA). "A" represents the wild allele, while "B" represents the mutation allele. After excluded studies not according to HWE, we conducted the subgroup analysis based on ethnicity (divided into Asian and Caucasian), cancer type, and source of control. All statistical analyses were calculated with the software STATA (Version 14.0; Stata Corp, College Station, TX).

SUPPLEMENTARY MATERIALS TABLE {#s5}
=============================
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